8-K: Nevro Reports Mixed Q4 Results, Provides 2024 Guidance Amid Restructuring

Nevro Corp. announced its fourth-quarter and full-year 2023 financial results, showing revenue growth but also a net loss, while providing 2024 guidance and highlighting strategic changes.

Summary

• Nevro reported a 2% increase in worldwide revenue for the fourth quarter of 2023, reaching $116.2 million.
• Painful Diabetic Neuropathy (PDN) indication sales saw a significant 29% increase, totaling approximately $22.4 million.
• U.S. trial procedures decreased by about 1%, while U.S. PDN trial procedures accounted for 24% of total U.S. trials.
• The company reported a net loss from operations of $11.8 million for the fourth quarter of 2023, but adjusted EBITDA was $8.4 million.
• Nevro acquired Vyrsa Technologies in November 2023 for a minimally invasive treatment option for sacroiliac joint pain.
• A $200 million term loan was secured to repurchase convertible notes, fund the Vyrsa acquisition, and for working capital.
• In January 2024, Nevro implemented a restructuring, laying off 5% of its workforce, primarily internally focused employees.
• Full-year 2024 revenue is projected to be between $435 million and $445 million, a 2% to 5% growth, with adjusted EBITDA expected to be between negative $8 million and negative $14 million.
• First-quarter 2024 revenue is expected to be between $97 million and $99 million, with adjusted EBITDA between negative $15 million and negative $16 million.
• Full-year 2023 worldwide revenue was $425.2 million, a 5% increase from 2022, including $77.9 million from PDN sales.
• The full-year 2023 net loss from operations was $99.3 million, compared to a net income of $6.2 million in 2022, which included $105 million in litigation-related credits.
• Full-year 2023 adjusted EBITDA was negative $17.7 million, an improvement from negative $23.8 million in 2022.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects like revenue growth and improved EBITDA in Q4, the company is still reporting losses and projecting losses for the next year. The restructuring and workforce reduction also contribute to a cautious outlook.

Positives

• Worldwide revenue increased by 2% in the fourth quarter of 2023.
• Painful Diabetic Neuropathy (PDN) sales saw a substantial 29% increase in the fourth quarter of 2023.
• The company's adjusted EBITDA improved significantly in the fourth quarter of 2023, reaching $8.4 million.
• Gross margin improved to 70.1% in the fourth quarter of 2023, driven by higher margin products and lower scrap charges.
• The acquisition of Vyrsa Technologies expands Nevro's product portfolio into the sacroiliac joint fusion space.
• The company secured a $200 million term loan to refinance debt and support operations.
• The restructuring is expected to positively impact full-year 2024 adjusted EBITDA by $14 million to $15 million.
• Over 115,000 patients have now been treated with HFX 10 kHz Therapy globally.

Negatives

• The company reported a net loss from operations of $11.8 million for the fourth quarter of 2023.
• U.S. trial procedures decreased by approximately 1% in the fourth quarter of 2023.
• The company expects a negative adjusted EBITDA for both the full year and first quarter of 2024.
• The restructuring included a 5% workforce reduction, impacting some employees.
• Full-year 2023 net loss from operations was $99.3 million.
• Litigation-related legal expenses increased to $2.9 million in Q4 2023 from $1.2 million in Q4 2022.

Risks

• The company faces risks related to commercializing its products and meeting demand.
• Third-party payor reimbursement levels and availability could impact revenue.
• The company's ability to manage growth and control operating costs is a risk.
• Intellectual property protection and potential infringement are ongoing concerns.
• Competition in the medical device industry could affect market share.
• The company's ability to integrate acquisitions, such as Vyrsa, is a risk.
• The company's ability to attract and retain qualified personnel is a risk.
• The company's ability to accurately forecast financial and operating results is a risk.
• Product liability claims could negatively impact the company.

Future Outlook

Nevro expects full-year 2024 revenue to be between $435 million and $445 million, representing 2% to 5% growth, and adjusted EBITDA to be between negative $8 million and negative $14 million. First-quarter 2024 revenue is expected to be between $97 million and $99 million, with adjusted EBITDA between negative $15 million and negative $16 million.

Management Comments

• Kevin Thornal, Nevro's CEO and president, stated that the fourth quarter performance reflects continued execution of their three-pillar strategy.
• Thornal also thanked the Nevro team for their dedication to freeing patients from chronic pain.
• Management is focused on advancing core strategic pillars of commercial execution, market penetration, and profit progress.

Industry Context

Nevro's results reflect the competitive landscape of the medical device industry, particularly in the chronic pain management sector. The acquisition of Vyrsa indicates a strategic move to expand into the sacroiliac joint fusion market, which is a growing area of interest. The company's focus on PDN also aligns with the increasing prevalence of diabetes and related neuropathic pain.

Comparison to Industry Standards

• Nevro's 2% revenue growth in Q4 2023 is modest compared to some high-growth medical device companies, but it is in line with expectations given the restructuring and market conditions.
• The 29% growth in PDN sales is a positive sign, indicating strong market adoption of their therapy for this indication.
• The adjusted EBITDA of $8.4 million in Q4 2023 is a significant improvement from the loss in the same quarter of the previous year, but the company is still projecting losses for 2024.
• Companies like Medtronic and Abbott, which also operate in the spinal cord stimulation market, have reported varying growth rates and profitability, making direct comparisons challenging without detailed segment data.
• The acquisition of Vyrsa is similar to other medical device companies expanding their portfolios through strategic acquisitions to gain market share in specific niches.

Stakeholder Impact

• Shareholders may be concerned about the net losses and negative adjusted EBITDA guidance for 2024.
• Employees have been impacted by the restructuring, with a 5% workforce reduction.
• Customers will benefit from the expanded product portfolio, including the Vyrsa acquisition.
• Suppliers may see changes in demand due to the restructuring and product portfolio changes.
• Creditors are impacted by the new $200 million term loan and the repurchase of convertible notes.

Next Steps

• Nevro will continue to focus on its three strategic pillars: commercial execution, market penetration, and profit progress.
• The company will work to integrate Vyrsa Technologies and its products into its portfolio.
• Nevro will monitor the impact of the restructuring on its financial performance.
• The company will host a conference call to discuss the financial results.

Key Dates

Keywords

Nevro, HFX, Spinal Cord Stimulation, Chronic Pain, PDN, Vyrsa Technologies, Sacroiliac Joint, Medical Device, EBITDA, Revenue, Restructuring, Financial Results